KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Basic): 2011-2024

Historic EPS (Basic) for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$0.28.

  • Esperion Therapeutics' EPS (Basic) fell 6.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 12.90%. This contributed to the annual value of -$0.28 for FY2024, which is 86.21% up from last year.
  • Latest data reveals that Esperion Therapeutics reported EPS (Basic) of -$0.28 as of FY2024, which was up 86.21% from -$2.03 recorded in FY2023.
  • Esperion Therapeutics' 5-year EPS (Basic) high stood at -$0.28 for FY2024, and its period low was -$9.31 during FY2021.
  • In the last 3 years, Esperion Therapeutics' EPS (Basic) had a median value of -$2.03 in 2023 and averaged -$1.94.
  • As far as peak fluctuations go, Esperion Therapeutics' EPS (Basic) slumped by 78.01% in 2021, and later spiked by 86.21% in 2024.
  • Esperion Therapeutics' EPS (Basic) (Yearly) stood at -$5.23 in 2020, then plummeted by 78.01% to -$9.31 in 2021, then skyrocketed by 62.19% to -$3.52 in 2022, then skyrocketed by 42.33% to -$2.03 in 2023, then surged by 86.21% to -$0.28 in 2024.